Jan. 10, 2012
Two new cross-border agreements were announced by Amerigen Pharma on January 11, 2012.
Under the terms of the agreement with Shanghai Fosun Omni Pharma, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the United States and other territories. Upon signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties for all commercialized products.
Amerigen also signed an MOU with VIWA Pharma, a Chinese company, to set up a JV that will develop and register a number of branded generics for sale in China.